selegiline has been researched along with oxepins in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furst, P; Kragten, E; Lalande, I; Muller, D; Roggo, S; Schindler, P; van Oostrum, J; Waldmeier, P; Zimmermann, K | 1 |
| Fürst, P; Kragten, E; Roggo, S; Waldmeier, P; Zimmermann, K | 1 |
| Borden, KE; Carlile, GW; Chalmers-Redman, RM; Pong, A; Tatton, NA; Tatton, WG | 1 |
| Hengerer, B; Spooren, WP; Waldmeier, PC | 1 |
| Boulton, AA; Cools, AR; Kato, AC; Tatton, WG; Waldmeier, PC | 1 |
| Jenner, P | 1 |
| LeWitt, PA | 1 |
| Drinkwater, D; Ji, Q; Liu, F; Pan, C; Vivilecchia, R; Wang, W | 1 |
| Bae, BI; Cascio, MB; Dawson, TM; Dawson, VL; Hara, MR; Hester, LD; Sawa, A; Snyder, SH; Thomas, B | 1 |
2 review(s) available for selegiline and oxepins
| Article | Year |
|---|---|
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline | 2004 |
Clinical trials of neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone | 2004 |
7 other study(ies) available for selegiline and oxepins
| Article | Year |
|---|---|
Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl.
Topics: Animals; Antiparkinson Agents; Apoptosis; Biosensing Techniques; Brain; Cell Line; Gene Expression Regulation; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Microscopy, Fluorescence; Molecular Structure; Muscles; Neuroblastoma; Neuroprotective Agents; Oligonucleotides, Antisense; Oxepins; Parkinson Disease; Photoaffinity Labels; Propylamines; Protein Binding; Rabbits; Rats; Selegiline | 1998 |
Synthesis of tools for target identification of the anti-apoptotic compound CGP 3466; Part I.
Topics: Animals; Apoptosis; Chromatography, Affinity; Fluorescent Dyes; Hippocampus; Indicators and Reagents; Molecular Structure; Neurons; Neuroprotective Agents; Oxepins; Rats; Selegiline; Structure-Activity Relationship | 1998 |
Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer.
Topics: Amphetamines; Animals; Apoptosis; Blood Proteins; Dimerization; Glyceraldehyde-3-Phosphate Dehydrogenases; Monoamine Oxidase Inhibitors; Nerve Growth Factor; Oxepins; PC12 Cells; Protein Conformation; Rats; Selegiline | 2000 |
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase | 2000 |
Neurorescuing effects of the GAPDH ligand CGP 3466B.
Topics: Animals; Animals, Newborn; Brain; Cell Survival; Cells, Cultured; Disease Models, Animal; Glyceraldehyde-3-Phosphate Dehydrogenases; Ligands; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Oxepins; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 2000 |
The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
Topics: Chromatography, Liquid; Drug Contamination; Gas Chromatography-Mass Spectrometry; Magnetic Resonance Spectroscopy; Mass Spectrometry; Oxepins; Pharmaceutical Preparations; Selegiline; Stereoisomerism | 2006 |
Neuroprotection by pharmacologic blockade of the GAPDH death cascade.
Topics: Animals; Antiparkinson Agents; Apoptosis; Cell Line; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; In Vitro Techniques; Male; Mice; MPTP Poisoning; Nerve Degeneration; Neuroprotective Agents; Nitric Oxide; Nuclear Proteins; Oxepins; Parkinson Disease; Selegiline; Ubiquitin-Protein Ligases | 2006 |